Introduction {#sec1}
============

Natural products, either directly or as inspiration, account for more than 50% of all small-molecule pharmaceutical agents in current clinical use ([@bib142]). By the end of 2013, natural products and derivatives possess about 38% of all US Food and Drug Administration-approved new molecular entities. However, the limited availability always becomes problematic when a bioactive natural product comes to a promising pharmaceutical ([@bib5]). Metabolic engineering endows cells with the ability of overproduction of new products, which provides a feasible approach for supplying these precious molecules ([@bib137]).

Advances in synthetic biology accelerated metabolic engineering toward more complex synthesis and sustainable supply of limited natural resources in the past 10 years. Successful heterogeneous synthesis of artemisinic acid ([@bib140]) and resveratrol ([@bib95]) highlighted the commercial feasibility of synthetic biology. Recently, the rapid development of synthetic biology enabled the microbial synthesis of more complex natural products, such as medicinal scutellarin ([@bib105]), alkaloids ([@bib97], [@bib171], [@bib173]), and cannabinoids ([@bib111]). These successes were achieved through several rounds of "Design-Build-Test-Learn (DBTL)," in which a lot of knowledge was obtained for next round. However, several urgent challenges remain in advancing microbial engineering as a general approach for the biosynthesis of natural products, including (1) the difficulty in identification of biosynthetic pathways, (2) the lack of suitable environment for heterologous expression of enzyme with best activity, (3) the disruption of intracellular homeostasis with heterologous complex biosynthetic pathways, and (4) the low metabolic flux toward biosynthetic pathway.

In this review, we first summarize the achievements made so far in the synthesis of natural products in yeast. Then we introduce the current advances in synthetic biology tools and metabolic engineering strategies at three dimensions (point, line, and plane), which are consistent with the general steps in building a cell factory. Point, line, and plane refer to individual optimization of engineering blocks (e.g., enzymes and cofactors), dynamic optimization of metabolic fluxes, and global optimization of cell robustness, respectively ([Figure 1](#fig1){ref-type="fig"}). In particular, we here discuss in detail the cofactor supply issue for retaining high activities of key enzymes other than their expression level. Meanwhile, we also present some perspectives to address the problems possibly encountered in the future.Figure 1Metabolic Engineering Strategies for natural Product Production in Three DimensionsPoint, line, and plane represent the individual enzymes and cofactors, metabolic pathways, and the global cellular network, respectively.

Production of Natural Products in Yeast {#sec1.1}
---------------------------------------

With the recent advances of functional genomics, metabolic engineering, systems and synthetic biology, a plenty of natural products or their precursors have been heterologously synthesized in microbes especially in the yeast cell factory. Here, we briefly introduce the yeast-based production of three types of most representative natural products: terpenoids, phenylpropanoids, and alkaloids ([Figure 2](#fig2){ref-type="fig"}).Figure 2Simplified Biosynthetic Pathways for Three Types of Natural ProductDifferent colors represent different types of natural products. The colored circles mean key precursors, and the colored rectangles mean intermediates. TCA, tricarboxylic acid cycle; PPP, pentose phosphate pathway; PPA, prephenate; Ac-CoA, acetyl coenzyme A; malonyl-CoA, malonyl coenzyme A; Phe, phenylalanine; Tyr, tyrosine; *p*-CA, *p*-coumaric acid; FPP, farnesyl diphosphate; GPP, geranyl diphosphate; GGPP, geranylgeranyl pyrophosphate; BIAs, benzylisoquinoline alkaloids; MIAs, monoterpene indole alkaloids; TAs, tropane alkaloids.

### Terpenoids {#sec1.1.1}

Terpenoids represent the largest class of natural products, which can be resources for pharmaceuticals, fragrances, and biofuels. The high-level production of artemisinic acid, the precursor of antimalarial artemisinin, showed the high potential of yeast *Saccharomyces cerevisiae* as a terpenoid cell factory ([@bib140]). The terpenoids have conserved skeletons with different amounts of isoprene units (C~5~H~8~), whose biosynthesis has been extensively reviewed elsewhere ([@bib85]). We here classified the current progress in engineering yeast for overproduction of terpenoids into two parts, including (1) engineering central metabolism for sufficient supply of the key shared precursor acetyl-CoA and pyrophosphate precursors: isopentenyl pyrophosphate/dimethylallyl pyrophosphate (IPP/DMAPP), geranyl pyrophosphate (GPP) for monoterpene, farnesyl pyrophosphate (FPP) for sesquiterpene, geranylgeranyl pyrophosphate (GGPP) for diterpene, etc., and (2) engineering downstream decorating pathways for diverse functional terpenoids.

In *S*. *cerevisiae*, the main cytosolic acetyl-CoA was biosynthesized from pyruvate dehydrogenase (PDH) bypass pathway (or pyruvate decarboxylation pathway), which, however, is strongly competed by ethanol fermentation. Thus a bacterial PDH was overexpressed in *S*. *cerevisiae* for direct conversion of pyruvate into acetyl-CoA in the cytosol ([@bib21], [@bib100]). However, the lack of cofactors such as lipoic acid (please refer to the section Engineering the Equilibrium State of Cofactors) for activating PDH ([@bib102]) limits the cytosolic PDH activity and the derived acetyl-CoA flux ([@bib86]). Alternatively, a non-native xylulose-5-phosphate-derived pathway was constructed for rewiring yeast central carbon metabolism to acetyl-CoA, which significantly boosted the farnesene production (130 g/L) with reduced requirement of ATP and oxygen ([@bib122]). The mitochondrial acetyl-CoA level is estimated to be 20- to 30-fold higher than that of the cytoplasm. Mitochondrial compartmentalization resulted \>2-fold higher production of amorpha-4,11-diene and isoprene production than the cytosolic biosynthetic pathway ([@bib114], [@bib211]).

With regard to enhancing pyrophosphate precursor supply, the limiting steps of mevalonate (MVA) pathway were enhanced by overexpression of the catalyzing enzymes or corresponding mutants with higher activity. For example, a truncated *tHMG1* or a variant *HMG2*^*K6R*^ was overexpressed for enhancing the activity of rate-limiting 3-hydroxy-3-methylglutaryl-coenzyme reductase (HMG-R) ([@bib71], [@bib222]). Furthermore, overexpression of *ERG10* (encoding acetoacetyl-CoA thiolase), *MK/ERG12* (encoding mevalonate kinase), and *MVD1* (encoding mevalonate pyrophosphate decarboxylase) were shown to be helpful in enhancing MVA flux for terpene biosynthesis ([@bib208]).

The 2-C-methyl-D-erythritol-4-phosphate (MEP) pathway synthesizes IPP by condensation of the glycolysis intermediates glyceraldehyde-3-phosphate (G3P) and pyruvate, which has higher theoretical yield of IPP than that of the yeast MVA pathway (1 versus 0.66 mol IPP per mol glucose) ([@bib93]). However, the lack of cytosolic \[4Fe-4S\] clusters for functional MEP key enzymes 1-hydroxy-2-methyl-butenyl-4-diphosphate (HMBPP) synthase (IspG) and HMBPP reductase (IspH), makes it challenging to reconstruct fully functional MEP pathway in yeast cytosol ([@bib83]). Alternatively, non-natural isoprenoid alcohol (IPA) pathway ([@bib33]) and isopentenol utilization pathway ([@bib24]) enabled biosynthesis of IPP and DMAPP without requiring the \[4Fe-4S\] clusters, which, however, have not been verified in yeast yet.

Monoterpene overproduction in *S*. *cerevisiae* is always challenging, because there is no specific GPP synthase. In *S*. *cerevisiae*, GPP is synthesized by a bifunctional enzyme ERG20p (farnesyl diphosphate synthase \[FPPS\]) and is rapidly utilized toward FPP by ERG20p, which limits the C10 precursor pool. Enzyme engineering created ERG20p mutants for specific GPP synthase activity ([@bib54], [@bib70]), which, however, hampered cell growth as the normal ERG20p is essential for the biosynthesis of essential cellular components. Construction of an orthogonal neryl diphosphate biosynthetic pathway enabled high-level production of monoterpenes without retarding cell growth ([@bib31], [@bib73]). Recently, a plethora of C11 terpenes were synthesized in *S*. *cerevisiae* by construction of chimeric pathway harboring GPP methyltransferase and monoterpene synthase mutants that prefer C11 pyrophosphate ([@bib73]). This non-natural terpene biosynthesis can expand chemical space and diversity of natural products for pharmaceutical development ([@bib221]).

Once terpene scaffolds are produced, multiple decoration steps, including oxidation, glycosyl transfer, and methyl transfer, work together to produce structurally diverse terpenoids ([@bib84]). The yeasts have been harnessed for heterologous synthesis of a variety of bioactive terpenoids, such as limonene, artemisinic acid, hydrocortisone, glycyrrhetinic acid, and ginsenosides ([Table 1](#tbl1){ref-type="table"}). Although systems biology approach can narrow the target genes, it is still challenging in identification and characterization of decoration enzymes. The yeast cells can be used for characterizing the enzymes in the biosynthesis of natural products such as tashinones ([@bib61], [@bib62]) and ginsenosides ([@bib204]) because of their clear backgrounds.Table 1Biosynthesis of Terpenoids, Alkaloids, and Phenylpropanoids in YeastsCompound NameActivityHostCultivation ConditionTiter (mg/L)Reference**Terpenoids**LimoneneFlavors, antibacterial and insecticide*S*. *cerevisiae*Semi-batch, CM166([@bib73])SabineneFlavors, antibacterial and insecticide*S*. *cerevisiae*Semi-batch, CM113([@bib73])GeraniolAntimicrobial and antitumor*S*. *cerevisiae*Fed-batch, CM1680([@bib77])α-TerpineolFlavors and anti-fungal*S*. *cerevisiae*Fed-batch, CM21.9([@bib214])Artemisinic acidAntimalarial*S*. *cerevisiae*Fed-batch, MM + glucose/ethanol25,000([@bib140])ValenceneFlavors and fragrances*S*. *cerevisiae*Fed-batch, MM539([@bib29])Valerenic acidAnxiolytic and sedative*S*. *cerevisiae*Shake flask, CM4.0([@bib199])PatchoulolNeuroprotection, anti-inflammatory, and anti-cancer*S*. *cerevisiae*Fed-batch, CM + glucose/glycerol/ethanol466.8([@bib117])SclareolAntibacterial and fragrances*S*. *cerevisiae*Shake flask, MM403([@bib71])MiltiradieneAntibacterial, anti-inflammatory, and anti-cancer*S*. *cerevisiae*Fed-batch, SMM365([@bib222])HydrocortisoneAnti-inflammatory*S*. *cerevisiae*Shake flask, CM1060([@bib30])Carnosic acidAntioxidation, anti-inflammatory, and anti-tumor*S*. *cerevisiae*Shake flask, MM2.7([@bib162])Ginsenoside Rh2Cancer prevention and therapy*S*. *cerevisiae*Fed-batch, CM2250([@bib193])Ginsenoside Rg3Anti-tumor and anti-cancer*S*. *cerevisiae*Shake flask, CM49.8([@bib189])Glycyrrhetinic acidAnti-viral, hepatoprotective, anti-allergic and antiulcer*S*. *cerevisiae*Fed-batch, CM18.9([@bib227])LycopeneAnti-tumor, cardiovascular protection, anti-cancer, antioxidation*S*. *cerevisiae*Fed-batch, CM + glucose/ethanol2370([@bib118])(+)-NootkatoneAnti-platelet aggregation and anti-proliferative*K*. *phaffii*Fed-batch, MM208([@bib200])(+)-AmbreinAnti-nociceptive and aphrodisiac*K*. *phaffii*Fed-batch, MM105([@bib130])LycopeneAnti-tumor, cardiovascular protection, anti-cancer, antioxidation*K*. *phaffii*Fed-batch, MM714([@bib216])α-SantaleneAntibacterial and diuretic*Y*. *lipolytica*Fed-batch, CM27.9([@bib76])LimoneneFlavors, antibacterial and insecticide*Y*. *lipolytica*Shake flask, CM23.6([@bib19])(+)-NootkatoneAnti-platelet aggregation and anti-proliferative*Y*. *lipolytica*Shake flask, CM0.98([@bib63])ProtopanaxadiolAnti-cancer, anti-tumor, anti-viral, and antibiotic*Y*. *lipolytica*Fed-batch, CM + xylose301([@bib201])CampesterolAnti-inflammatory*Y*. *lipolytica*Fed-batch, CM453([@bib44])Ginsenoside KAntitumor and anti-inflammatory*Y*. *lipolytica*Fed-batch, CM162([@bib98])AstaxanthinAntioxidant*Y*. *lipolytica*Fed-batch, CM285([@bib182])**Alkaloids**Opioids (thebaine, hydrocodone)Pain killer*S*. *cerevisiae*Shake flask, MM0.3--6.4\*10^−3^([@bib56])NoscapineAnti-cancer and anti-tussive*S*. *cerevisiae*Shake flask, CM2.2([@bib97])StrictosidineAnti-cancer*S*. *cerevisiae*Shake flask, MM0.5([@bib16])TropineTreatment for neurological disorder*S*. *cerevisiae*Fed-batch, SM6.0([@bib171])PseudotropineAnticholinergic*S*. *cerevisiae*Shake flask, CM0.08([@bib145])BetaninFood dye and spectrofluorometric probes*S*. *cerevisiae*Shake flask, MM16.8([@bib60])**Phenylpropanoids**ResveratrolNutraceutical and antioxidation*S*. *cerevisiae*Fed-batch, MM + ethanol531([@bib95])ScutellarinCardio- and cerebrovascular diseases prevention*S*. *cerevisiae*Fed-batch, MM108([@bib105])Anthocyanin (pelargonidin-3-O-glucoside, cyanidin-3-O-glucoside, delphinidin-3-O-glucoside)Antioxidation, neuroprotection, vision improvement, cardiovascular protection, antidiabetic, anti-inflammatory*S*. *cerevisiae*Shake flask, MM0.85--1.86([@bib48])8-PrenylnaringeninPotential treatment to adverse symptoms of menopause*S*. *cerevisiae*Shake flask, MM0.12([@bib92])KaempferolAnti-cancer, anti-inflammatory effects*S*. *cerevisiae*Shake flask, CM86.8([@bib116])FisetinAnti-cancer, cardio-protective, and anti-inflammatory*S*. *cerevisiae*Shake flask, MM2.3([@bib156])QuercetinCardiovascular protection*S*. *cerevisiae*Shake flask, MM20.4([@bib156])Dihydrochalcones (phlorizin, naringin dihydrochalcone, nothofagin)Hypoglycemic agent, antioxidation*S*. *cerevisiae*Shake flask, MM11.6--65.0([@bib47])Raspberry ketoneFlavoring agent*S*. *cerevisiae*Shake flask, CM3.5([@bib91])NaringeninNeuroprotective and antioxidation*S*. *cerevisiae*Shake flask, MM100([@bib92])SalidrosideAnti-cancer, cardiovascular, nerve, and brain cell protection*S*. *cerevisiae*Fed-batch, MM732([@bib78])3′-HydroxygenisteinAntioxidant, antiproliferative, anti-inflammatory, and anti-melanogenesis*K*. *phaffii*Shake flask, CM23.0([@bib190])NaringeninNeuroprotective and antioxidation*Y*. *lipolytica*Fed-batch, MM898([@bib141])EriodictyolAntioxidant and antiaging*Y*. *lipolytica*Shake flask, MM134([@bib115])TaxifolinAnticancer, anti-inflammatory, and antidiabetic*Y*. *lipolytica*Shake flask, MM111([@bib115])[^2]

Other than the budding yeast *S*. *cerevisiae*, some other yeasts have also been harnessed for the production of terpenoids. *Yarrowia lipolytica* is a non-conventional oleaginous yeast, which is supposed to be a valuable host for the production of terpenoids due to its own endogenous MVA pathway and high acetyl-CoA biosynthesis with high oil production capacity ([@bib119]). Indeed, *Y*. *lipolytica* has been engineered for producing a plethora of bioactive terprnoids such as ginsenoside ([@bib98]) and nootkatone ([@bib63]). The methylotrophic yeast *Komagataella phaffii* (previously named as *Pichia pastoris*) has also been engineered for the production of lycopene ([@bib11]) and nootkatone ([@bib200]). However, the limited genetic tools hindered the extensive metabolic rewiring, which resulted in much lower production than that in *S*. *cerevisiae* ([Table 1](#tbl1){ref-type="table"}).

### Alkaloids {#sec1.1.2}

Alkaloids are a class of natural products that mostly contain basic nitrogen atoms that include analgesic, sedative, and anti-cancer agents ([@bib46], [@bib80], [@bib139]). Recently, it is attracting more attention to engineer yeast for the synthesis of alkaloids such as benzylisoquinoline, monoterpene indole, and tropane alkaloids (BIAs, MIAs and TAs) ([@bib16], [@bib135], [@bib171]).

BIAs biosynthetic pathway can be divided into two parts ([Figure 2](#fig2){ref-type="fig"}): the production of the key branchpoint metabolite (S)-reticuline and the downstream modification ([@bib183]). Although high-level production of (S)-reticuline has been achieved in *Escherichia coli* ([@bib128], [@bib132]), it is still challenging in the efficient biosynthesis of (S)-reticuline in *S*. *cerevisiae* due to the difficulties in functional expression of bacterial tyrosinase that specifically catalyzes tyrosine hydroxylation toward L-3,4-dihydroxyphenylalanine (L-DOPA) ([@bib40]). Instead of tyrosinase, tyrosine hydroxylases (THs) and cytochrome P450 hydroxylase CYP76AD1 can serve as alternative options for L-DOPA production in *S*. *cerevisiae* ([@bib135]). Although TH has high specificity toward L-DOPA biosynthesis, it is heavily allosterically inhibited by substrate tyrosine and requires cofactor 5,6,7,8-tetrahydrobiopterin (BH4) ([@bib37]). A feedback inhibition-resistant mutant TH∗ ([@bib97]) and reconstruction of BH4 biosynthetic module (please refer to the section Reconstruction of Cofactor Biosynthesis) enabled efficient biosynthesis of (S)-reticuline. Similarly, expression of a CYP76AD1 mutant with abolished side activity enhanced L-DOPA biosynthesis in *S*. *cerevisiae* ([@bib40], [@bib65]).

The (S)-reticuline-overproducing strain provides the chassis for the synthesis of versatile BIAs in *S*. *cerevisiaec* ([Table 1](#tbl1){ref-type="table"}). With integration of downstream modification enzymes, more and more BIAs were successfully *de novo* synthesized in *S*. *cerevisiae*, such as thebaine ([@bib173]) and noscapine ([@bib97], [@bib173]). It is worthy to mention that up to 30 genes from various species were functionally expressed in *S*. *cerevisiae* for BIA biosynthesis, which demonstrated the high potential and capacity of yeast cell factories for natural product biosyntheses ([@bib97]). However, the yield of alkaloids in yeast remains low, which is commonly believed to be caused by insufficient core precursor (S)-reticuline ([@bib40], [@bib173]).

MIAs are a diverse family of complex nitrogen-containing plant-derived metabolites, which were composed of a secoiridoid moiety and an indole moiety with very diverse structures. Reconstruction of a seven-step pathway in *S*. *cerevisiae* enabled the production of anti-cancer drug precursor vindoline from tabersonine ([@bib149]). Reconstruction of a plant-derived pathway with 15 genes, along with deletion of side pathways and enhancement of precursor supply, enabled for the first time *de novo* the biosynthesis of strictosidine in yeast ([@bib16]).

TAs, containing common tropane ring, are a group of more than 200 specialized metabolites naturally produced in most solanaceous plants, which are widely used for treating nerve agent poisoning, gastrointestinal spasms, cardiac arrhythmia, and symptoms of Parkinson disease. With the characterized enzyme from a Chinese medical plant *Anisodus acutangulus*, the six-step biosynthetic pathway was reconstructed for *de novo* biosynthesis of tropine and pseudotropine (about 0.1 mg/L) in *S*. *cerevisiae* ([@bib145]). Almost at the same time, the yeast central metabolism was extensively rewired for improving precursor supply and relieving the side pathway competition, which enabled much higher tropine production of 6 mg/L. With this chassis platform, the non-natural TA cinnamoyltropine was *de novo* synthesized by coupling biosynthetic modules from diverse plant lineages, which may accelerate the drug discovery pipeline ([@bib171]).

### Phenylpropanoids {#sec1.1.3}

The phenylpropanoids are commonly derived from L-tyrosine in microorganisms ([@bib74]) and L-phenylalanine in plants ([@bib66], [@bib79]). The phenylpropanoid biosynthesis can be divided into two modules: the module for supplying precursor *p*-coumaric acid (*p*-CA) and the functional decoration module. Rewriting the central carbon metabolism, combined with the microbial tyrosine ammonia lyase and plant cinnamic acid hydroxylase branches, enabled high-level production of *p*-CA (12.5 g/L) in *S*. *cerevisiae* ([@bib110], [@bib154], [@bib155]). Several flavonoids and simple polyphenols such as scutellarin, anthocyanin, and resveratrol have been successfully heterologously synthesized in yeast ([Table 1](#tbl1){ref-type="table"}). However, there is no report regarding engineering yeast for the synthesis of complex phenylpropanoids, such as active lignan clemastanin B ([@bib213]), and etoposide ([@bib89]), which mainly contributed to the complexity of downstream decoration steps. The very poor specificity of downstream enzymes can lead to accumulations of many by-products. For example, 4-coumaric acid:CoA ligase can in a promiscuous manner convert the *p*-CA and caffeic acid to the corresponding CoA molecules, which limits the pathway efficiency. Compartmentalization and co-cultivation may be feasible approaches to address this problem, which mimics spatiotemporal control in plants to avoid metabolic interference ([@bib28], [@bib188]). Recently, *Y*. *lipolytica* has been engineered as a phenylpropanoid-derived polyketide producer due to its high fluxes of acetyl and malonyl-CoA precursors, which were benefited from increased β-oxidation and peroxisome numbers, and overexpression of acetyl-CoA carboxylase (ACC1) ([@bib141]). Many attempts archived production of phenylpropanoid-derived polyketides in other non-conventional yeasts, such as flavonoids in *Y*. *lipolytica* ([@bib115]) and *K*. *phaffii* ([@bib190]) and triacetic acid lactone in *Y*. *lipolytica* ([@bib107]).

Enzyme Discovery {#sec1.2}
----------------

To date, more than 45,000 genomes are available in public databases, providing abundant resources for gene discovery. Even many functional genes and secondary metabolic pathways have been identified through the combination of computational mining and experimental confirmation ([@bib229]), it is still challenging to identify suitable enzymes for the construction of biosynthetic pathways in specific hosts. Heterologous protein expression in yeast often results in reduced activity or undesired catalytic properties, because of incorrect folding, low expression levels, unsuitable microenvironments or feedback inhibition, etc. ([@bib164]). Here, we will discuss the advanced approaches to get suitable enzymes and regulation components for efficient biosynthetic pathways.

### Multi-species Genomes Provide Clues for Enzyme Discovery {#sec1.2.1}

Specific biosynthesis can be conducted by different pathways (even different enzymes) among various species due to evolution diversity. There will be low efficiency when wholesale adopting inherent biosynthetic pathway from single species into a heterologous host. Alternatively, combinatorial optimization by using alternative steps or isoenzymes from multi-species genomes may result in efficient biosynthetic pathways ([@bib173]) ([Figure 3](#fig3){ref-type="fig"}A). For example, non-natural IPA pathway was reconstructed for isoprenoid biosynthesis by combining multi-species genes from *Staphylococcus aureus*, *Myxococcus xanthus*, *Clostridium beijerinckii,* and *E*. *coli*. This novel IPA pathway is more energy efficient than native MVA and MEP pathways, resulting in the production of 0.6 g/L monoterpenoids from glycerol ([@bib33]). As mentioned above, integration of four non-native metabolic reactions in *S*. *cerevisiae* improved acetyl-CoA supply and enabled high-level production of farnesene with reduced ATP requirement and carbon loss ([@bib122]). The production of caffeic acid from coumaric acid in plants requires multiple steps of oxidation and esterification, which are very weak in plant and yeast ([@bib108], [@bib157]). A shorter and more efficient pathway catalyzed by HpaB (4-hydroxyphenylacetate 3-monooxygenase) and HpaC (NADPH-flavin oxidoreductase) from bacteria was constructed to replace the native plant pathway in *E*. *coli* and *S*. *cerevisiae*, which significantly improved conversion of coumaric acid toward caffeic acid ([@bib52], [@bib108], [@bib191]).Figure 3Strategies for Enzyme Discovery And Engineering(A) Multi-species genomes are a treasure trove of versatile enzymes. Integration of enzymes from multiple species (bacteria, fungus, virus, plant, and animal) for the construction of chimeric pathway is beneficial for optimization of natural product biosynthesis.(B) Knowledge-driven protein engineering is a promising approach to rational enzyme design for specific catalysis. The letters E and E′ indicate the structure comparison of the original protein and rationally engineered protein. The red rectangles represent the engineered proteins, and the asterisks represent the mutation sites. In the chromatogram the ticks represent the functional mutants.(C) Biosensor is an ideal strategy for high-throughput screening of desired enzymes according to intuitive phenotypic changes. The brightness of bulbs and the circle color represent the response intensity of the biosensor and the yield of the product, respectively.

These studies clearly demonstrated that the construction of chimeric pathways, by integration of multiple species genes, is beneficial for efficient biosynthesis of molecules of interest, which, however, strongly relies on the identification of efficient functional genes from the avalanche gene databases. Fortunately, extensive bioinformatic tools and high-throughput experimental data were developed to elucidate biological function from multi-species genomes ([@bib13], [@bib123], [@bib229]), which should facilitate the identification of efficient enzymes for construction of biosynthetic pathways.

### Knowledge-driven Protein Engineering {#sec1.2.2}

Other than gene excavation from multi-species genomes, knowledge-driven or rational protein engineering is a more targeted strategy to improve enzyme specificity and efficiency with the aid of protein crystal structure and computer simulation ([Figure 3](#fig3){ref-type="fig"}B). Furthermore, protein engineering can help to create efficient enzymes for specific reactions without available enzymes, by engineering the promiscuous enzymes from similar reaction.

In *S*. *cerevisiae*, ERG20p catalyzes consecutive reactions for the biosynthesis of GPP (C10) and FPP (C15) by consecutively condensing IPP and DMAPP (C5 units). To improve the monoterpene and diterpene production, ERG20p was engineered into a double-mutant GPP synthase (F96W-N127W) ([@bib70]) and a single-mutant GGPP synthase (F96C or Y95A) ([@bib71]), through protein engineering, when compared with previously identified crystal model of the avian FPPS ([@bib172], [@bib178]). Similarly, ERG20p was specifically engineered to a non-natural C11 terpene synthase by a single-residue switch, which enabled the biosynthesis of a serious of non-natural C11 terpenes in *S*. *cerevisiae* ([@bib72]). With the development of structural biology, more and more crystal structures of catalytic enzyme have been resolved, which laid the foundation for the homology model construction and directed evolution. Knowledge-driven or rational protein engineering can provide more efficient enzymes for construction of robust yeast cell factories ([@bib88], [@bib154], [@bib220]).

### Biosensor for High-Throughput Screening {#sec1.2.3}

Biosensor is an ideal strategy for high-throughput screening of desired homologous proteins or mutants ([@bib32]), which requires a certain correlation between biosensor and the enzyme activity with an easily observed signal, such as color, fluorescence, or growth state ([Figure 3](#fig3){ref-type="fig"}C).

Even the synthesis of (S)-reticuline from glucose was already achieved in *E*. *coli* ([@bib132]), non-functional TH limited the synthesis of BIAs in *S*. *cerevisiae* ([@bib67]). A small-molecule biosensor was developed by setting a negative correlation between the activity of TH and yellow by-product betaxanthin, which achieved high-throughput screening of TH mutants for the efficient synthesis of upstream intermediate L-DOPA and a 7.4-fold improvement of dopamine production with the best mutant ([@bib40]). Transcription factor-based biosensor is much more commonly used and can directly respond to molecules with conformational change of transcription factors ([@bib198]). Using a bacterial transcription factor FapR and its corresponding operator fapO, a malonyl-CoA biosensor was constructed in *S*. *cerevisiae* to gauge and improve intracellular malonyl-CoA levels ([@bib96]). The yeast-based biosensor was also successfully used in the screening of itaconic acid ([@bib49]) and short-/medium-chain fatty acids producer ([@bib9]).

Cofactor Engineering {#sec1.3}
--------------------

Although great progresses have been achieved in reconstruction of metabolic pathways for natural products, heterologous expression of enzymes from other species such as plants may encounter low-efficiency or inactive forms due to the lack of suitable cofactors ([Figure 4](#fig4){ref-type="fig"}A). In particular, eukaryotic organisms have compartmentalized cellular metabolism and distinct cofactor distribution in sub-organelles. For example, cytosolic reconstruction of cytochrome P450 enzyme-containing pathways may have insufficient cofactor heme ([@bib126], [@bib176]), which is mainly localized in the mitochondria for maintaining efficient redox reactions. [Figure 4](#fig4){ref-type="fig"}B shows the biosynthetic pathways of redox-related cofactor (pairs) in *S*. *cerevisiae* and the mutual transformation in central carbon metabolism, which clearly demonstrates the complexity of cofactor regulation in eukaryotic cells. Although the role of NAD(P)^+^/NAD(P)H on regulating cellular redox balance and metabolic flux has been extensively reviewed elsewhere ([@bib25], [@bib187], [@bib192]), we here, for the first time, compressively review how the cofactors affect the biosynthetic pathways and cofactor regulation strategies for improved biosynthesis.Figure 4Cofactor Engineering for Enhancing Biosynthetic Efficiency of Natural Products(A) Representative cofactors involved in natural product biosynthesis. Two different states (X and Y) of cofactors keep cellular hemostasis. The squares and circles represent the substrates and natural products (NP), respectively.(B) The biosynthetic pathways of redox-related cofactors in *S*. *cerevisiae*. Circles represent metabolites; yellow and blue circles represent metabolites involved in cofactor transformation and cofactor biosynthesis, respectively.(C--F) Different regulation strategies of cofactors: Cofactor biosynthesis reconstruction (C), enhancing cofactor level (D), cofactor recycling (E), and cofactor activation (F). a denotes substrate, b denotes intermediates, and NP stands for natural products. Triangles of different colors represent cofactors of different forms. NAD^+^, nicotinamide adenine dinucleotide; NADP^+^, nicotinamide adenine dinucleotide phosphate; NADH, reduced from of NAD^+^; NADPH, reduced from of NADP^+^; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; FADH~2~, reduced from of FAD; FMNH~2~, reduced form of FMN; SAM, S-adenosyl methionine; SAH, S-Adenosyl-L-homocysteine; V~H~, biotin; V~H~-COOH, carboxylated biotin; S-L-S, lipoamide; SH-L-SH, dihydrolipoamide; =Co^3+^ = , 5′-deoxyadenosylcobalamin (vitamin B12); A-Co^3+^, inactive vitamin B12; PLP-E, pyridoxal-5-phosphate-protein complex; PLP-N, PLP aldimine; GTP, guanosine triphosphate; RF, riboflavin; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; G3P, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone phosphate; 1,3-BPG, 1,3- bisphosphoglycerate; PYR, pyruvate; AH, acetaldehyde; EtOH, ethanol; ACE, acetate; Ac-CoA, acetyl-CoA; GδL6P, 6-phosphoglucono-δ-lactone; 6PG, 6-phosphoglucononate; Ru5P, ribulose-5-phosphate; R5P, ribose-5-phosphate; Xu5P, xylulose-5-phosphate; S7P, sedoheptulose-7-phosphate; E4P, erythrose-4-phosphate; CIT, citrate; ICIT, isocitrate; α-KG, α-ketoglutarate; SUCCoA, succinyl-CoA; SUCC, succinate; FUM, fumarate; MAL, malate; OAA, oxaloacetate; NAM, nicotinamide.

### Reconstruction of Cofactor Biosynthesis {#sec1.3.1}

Some enzymes often require special cofactors to achieve high catalytic activities. Heterologous expression of enzymes derived from plant and other species in yeast may suffer from insufficient or deficient cofactor supply, due to the different cellular environment between yeast and their natural hosts. Thus, reconstituting the cofactor biosynthesis should be helpful for maintaining the high enzyme activity for efficient natural product biosynthesis in yeast ([Figure 4](#fig4){ref-type="fig"}C).

Previously studies found that plant TH had low activity in *S*. *cerevisiae* ([@bib40], [@bib67]), which limited the alkaloid biosynthesis in yeast. The main reason is the deficiency of its cofactor BH4 in yeast ([@bib55]). Thus, BH4 biosynthetic pathway was reconstituted and enabled the significant noscapine biosynthesis in *S*. *cerevisiae* ([@bib97]). We also found that reconstruction of bacterial NADPH-dependent electron transfer systems, Fd/Fnr (ferredoxin-ferredoxin reductase) and Fld/Fnr (putidaredoxin-putidaredoxin reductase), significantly improved the performance of bacterial alkane and 1-alkene biosynthetic pathways in yeast ([@bib17], [@bib225]).

Biotin acts as a cofactor for biotin-dependent carboxylases involved in essential carboxylation and decarboxylation reactions ([@bib174]). Most yeasts are deficient in *de novo* biosynthesis of biotin or have insufficient level for fast growth and product formation ([@bib144]) and thus require external addition of this expensive vitamin in cultures. Laboratory evolution rendered full biotin prototrophy of *S*. *cerevisiae,* and genome sequencing revealed causal mutations for biotin deficiency in *S*. *cerevisiae* ([@bib15]), which should be helpful for the construction of biotin-dependent biosynthetic pathways in yeast.

Pyridoxal 5′-phosphate (PLP), one of the most versatile cofactors, is essential for over 160 enzymes ([@bib42]), and is synthetized through the ribose-5-phosphate-dependent *de novo* and salvage pathways. Therefore, PLP plays an important role in natural product biosynthesis ([@bib163]), because PLP-dependent enzymes catalyze diverse chemical reactions, including decarboxylation, transamination, racemization, Cα-Cβ bond cleavage, and α, β-elimination reaction. Supplementation of PLP and eliminating its degradation significantly improved the whole-cell transamination for stereoselective production of (R)-1-phenylethylamine (\>99% enantiomeric excess) in yeast *S*. *cerevisiae* ([@bib196], [@bib197]). Similarly, using a PLP-dependent Rosa hybrid phenylacetaldehyde synthase along with internal *de novo* PLP synthesis produced 0.34 g/L 2-phenylethanol for the first time in *E*. *coli* ([@bib1]).

The eukaryotic cell metabolism is compartmentalized in sub-organelles, whose membranes are impermeable to various cofactors. Thus, it is necessary to reconstitute cofactor biosynthesis to drive the corresponding cofactor-dependent biosynthetic pathways in specific sub-organelles even if there is cofactor localization in other sub-organelles ([Figure 4](#fig4){ref-type="fig"}C). PDH complex consists of three catalytic subunits, PDH (E1), dihydrolipoyl transacetylase (E2), and dihydrolipoyl dehydrogenase (E3), which catalyze the efficient conversion of pyruvate to acetyl-CoA in yeast mitochondria. Reconstruction of PDH into cytosol is an ideal strategy for enhancing cytosolic acetyl-CoA supply without accumulation of by-product ethanol, which would be beneficial for biosynthesis of acetyl-CoA-derived molecules such as terpenoids and polyketides. However, it is challenging in cytosol reconstruction of PDH, because the biosynthesis of cofactor lipoic acid for E2 subunit activation localizes in mitochondria. Thus, external lipoic acid supplementation and reconstruction of cytosolic lipoic acid biosynthetic pathways are prerequisites for functional assembly of cytosolic PDH ([@bib86], [@bib102]).

### Enhancing the Cofactor Level {#sec1.3.2}

The cellular cofactor levels determine the metabolic flux, because cofactors involve enzyme reactions and thus regulate chemical equilibrium state. Therefore, enhancing cellular cofactor levels by engineering their biosynthetic pathway could drive the metabolic flux toward biosynthesis of the target product ([Figure 4](#fig4){ref-type="fig"}D).

S-adenosyl-L-methionine (SAM) is a central cofactor that participates in a variety of reactions and physiological processes mainly as methyl donor ([@bib103], [@bib120], [@bib180]). Also, many natural product biosyntheses involve methylation steps catalyzed by SAM-dependent methyltransferases ([@bib43], [@bib230]). Many studies indicated that SAM level had a greater effect on methylation reactions than methyltransferase expression ([@bib27], [@bib87], [@bib218]). Although rarely reported in yeast metabolic engineering, it has been widely shown that up-regulation of SAM significantly improved the production of ephedrine ([@bib129]), vanillin ([@bib87]), and pterostilbene ([@bib68]) in *E*. *coli*.

Flavin is an active cofactor involved in maintaining redox homeostasis in mitochondria ([@bib57]), endoplasmic reticulum (ER) ([@bib81]), and nucleus ([@bib179]). Flavin adenine dinucleotide (FAD)-dependent monooxygenase (hpaB) enabled higher-level production of caffeic acid from *p*-CA than plant-specific cytochrome P450-dependent monooxygenase ([@bib7], [@bib108], [@bib191]). It is expected that this pathway will consume a large amount of cytoplasmic FADH~2~ and disrupt intracellular FADH~2~/FAD homeostasis, and enhancing FAD(H~2~) level will further improve caffeic acid production in yeast.

### Engineering the Equilibrium State of Cofactors {#sec1.3.3}

In addition to the cofactor levels, the cellular equilibrium states (the ratio between reducing and oxidation forms) affect the efficiency of the corresponding enzyme and even cellular redox hemostasis. The NAD^+^/NADH, NADP^+^/NADPH, FMN/FMNH~2~, and FAD/FADH~2~ cofactor pairs are important components of the electron transport chain and involved in at least 800 biochemical reactions ([@bib25]). Thus, engineering the cellular redox balance is important for increasing the biosynthesis of target compounds and robustness of cell factories ([Figure 4](#fig4){ref-type="fig"}E).

We previously reprogrammed *S*. *cerevisiae* metabolism from ethanol fermentation toward lipogenesis. Ethanol fermentation (Crabtree effect) is mainly attributed to the high NADH/NAD^+^ from efficient glycolysis, and ethanol biosynthesis can re-oxidize cytosolic NADH. Enhancing fatty acid biosynthesis required high level of NADPH, and blocking ethanol fermentation disturbed the cellular redox hemostasis. Redirecting NADH to NADPH by engineered transhydrogenase and pentose phosphate pathway, and down-regulating glycolytic flux for reduced NADH generation, resulted a Crabtree-negative yeast for high-level production of fatty acids ([@bib210]). It is worthy to mention that Crabtree effect can be relieved by enhancing the respiration of cytosolic NADH via external mitochondrial NADH dehydrogenases (NDE1/2) ([@bib8], [@bib113]). Many natural products involve P450-catalyzed tailoring steps, which require NADPH for electron transfer. For example, noscapine biosynthesis involves five P450 enzymes ([@bib184], [@bib205]), which would consume large amount of NADPH for high-level production of noscapine and disturb the balance of NADPH/NADP^+^. Thus the NADPH was enhanced by overexpressing NADH kinase, three isocitrate reductases, prephenate dehydrogenase, and NADP-dependent glycerol dehydrogenase (GCY1p), leading to significant improvement of noscapine production by using glycerol as carbon source ([@bib97]). 3-Hydroxypropionic acid (3-HP) biosynthesis from acetyl-CoA requires extensive NADPH-dependent reduction, which deprives the cellular reducing power. Coupling the glycolysis with NADPH regeneration by expressing an NADP^+^-dependent G3P dehydrogenase, enabled a 2-fold improvement of 3-HP in *S*. *cerevisiae* ([@bib25]). NADPH is the driving force for fatty acid biosynthesis; thus extensive redox engineering was implemented for converting NADH to NADPH in *Y*. *lipolytica*, which achieved a new redox equilibrium state and enabled a high-level lipid production of 90 g/L ([@bib147]).

### Increase the Active Form of Cofactors {#sec1.3.4}

Some cofactors do not work alone and require activation through covalent binding to the protein ([Figure 4](#fig4){ref-type="fig"}F). As mentioned above, lipoic acid is necessary for functional reconstruction of PDH in yeast cytosol, but it cannot directly activate E2 subunit of PDH. Its active form lipoamide functions as an acyl carrier for E2 activation by covalent attachment of the lipoic acid to the ϵ-amino group of a specific lysine residue of E2 ([@bib34], [@bib153]). Therefore, in addition to reconstruction of cytosolic lipoic acid biosynthesis, a *de novo* synthetic lipoylation machinery is also necessary for functional reconstitution of PDH in the yeast cytosol ([@bib102]).

Cofactor B12 is very important for glycerol dehydratase activity in 1,3-propanediol (1,3-PDO) production, which becomes inactive (B12-inact) when tightly bound to the dehydratase after the reaction with glycerol ([@bib160]). A protein partner (pduO), glycerol dehydratase reactivase, facilitates the dissociation of the B12-inact from glycerol dehydratase. Also, B12-inact is reconverted to B12-act with the participation of flavoprotein and ATP ([@bib138]). Thus, engineering rapid conversion of B12-inact into B12-act, in addition to increased B12 level, is very beneficial for enhancing glycerol dehydratase activity ([@bib23], [@bib134]).

Pathway Construction and Optimization {#sec1.4}
-------------------------------------

Despite the availability of versatile active enzyme elements and cofactors, it is still challenging in heterologous reconstruction of the efficient biosynthesis pathways, which is influenced by the complex interactions between metabolites and enzymes as well as the severely disturbing endogenous cellular metabolism. Several strategies, including relieving feedback inhibition, dynamic pathway regulation, and metabolon construction, were developed for improving the biosynthesis in yeast cell factories ([Figure 5](#fig5){ref-type="fig"}).Figure 5Strategies to Enhance the Metabolic Flux of Natural Product Biosynthesis(A) Eliminating feedback inhibition of key enzymes and blocking the side pathways for reducing by-product accumulation. Squares, circles, and triangles represent intermediate, target products, and by-products, respectively.(B) Dynamic regulation of pathway activation through biosensor. BD and AD represent the binding domain and active domain of the transcription factor, respectively, which form the effector for gene activation.(C) Protein fusion for substrate channeling.(D) Scaffold enables boding enzymes for enhancing substrate channeling.(E) Sub-organelle compartmentalization of heterogeneous pathways. Sub-organelle number and size can be engineered for enhancing biosynthesis.(F) Co-culture engineering among multiple microorganisms, such as bacteria-bacteria, bacteria-yeast, and yeast-yeast, for improving natural products biosynthesis.

### Eliminate Feedback Inhibition of Key Enzymes {#sec1.4.1}

The feedback inhibition mentioned here refers specifically to product inhibition at the enzyme level, not at the transcription level ([@bib217]) ([Figure 5](#fig5){ref-type="fig"}A). Introduction of feedback-insensitive amino acid biosynthetic genes (*ARO4*^*K229L*^ and *ARO7*^*G141S*^) improved cellular aromatic compound levels by 200-fold in *E*. *coli* and *S*. *cerevisiae* ([@bib12], [@bib154]). Characterizing and expressing a non-feedback acetyl-CoA synthetase mutant from *Salmonella enterica* increased the production of acetyl-CoA/malonyl-CoA-derived products in yeast by enhancing acetyl-CoA supply ([@bib22]). This strategy is generally based on a clear understanding of the enzyme structure and inhibition mechanism. Otherwise, biosensor-based enzyme engineering may be helpful for screening feedback-insensitive mutants (as mentioned in the section Biosensor for High-Throughput Screening).

### Dynamic Regulation {#sec1.4.2}

Heterologous biosynthetic pathways may bring enormous stress on the cell fitness, such as the accumulation of toxic intermediates, the competition of carbon sources, and reducing power. Dynamic regulation of biosynthetic pathways may relieve the stresses by separating the cell growth and product biosynthesis. A dynamic control system comprises two elements: a sensor that perceives external environment change and an effector that can respond to the sensor ([@bib148]) ([Figure 5](#fig5){ref-type="fig"}B).

The carbon source sensor is extensively used for the construction of dynamic pathway, such as GAL and HXT systems. The promoters of galactose metabolism genes, such as *GAL1p* and *GAL10p,* are activated by galactose and repressed by glucose in *S*. *cerevisiae* ([@bib3]). With deletion of *GAL80*, these GAL promoters are constitutively transcribed at low glucose level and can be used for the construction of biosynthetic pathways responding to glucose level, which can divide fermentation process into cell growth and product biosynthesis phases. The GAL system has derived a variety of dynamic regulation strategies to meet different needs, which provides a tool for further refined control of metabolic engineering ([@bib143], [@bib159]). The promoter of hexose transporters (*HXT1p*, *HXT6p,* and *HXT7p*) were used to dynamically regulate by-product biosynthesis pathways ([@bib161]) and fatty alcohol transporter ([@bib69]) with relieved yeast cell stresses.

Optogenetic regulation is an easily operational strategy for dynamic control of biosynthetic pathways, as light can be applied and removed easily without complex media changes ([@bib219]). A blue-light-responsive circuit was constructed by using a blue light transcription factor EL222 from the marine bacterium *Erythrobacter litoralis* ([@bib136]), for dynamically activating cell growth upon blue light exposure and product biosynthesis in the dark ([@bib219]). This optogenetic regulation strategy successfully separated isobutanol biosynthesis from cell growth and improved the production of isobutanol by more than three times, which relieved the toxicity of isobutanol ([@bib219]). Although this strategy is easy operating, the permeability of light should be addressed for industrial high-density fermentation.

### Metabolic Compartmentalization {#sec1.4.3}

Natural product biosynthesis always involves complex multi-step pathways, and reconstruction of yeast cell factory often encounters some common challenges, such as unsuitable physicochemical environments (pH and redox potential), insufficient supply of essential materials (substrates and cofactors), occurrence of undesired side reactions, toxicity of intermediates, and incompatibility with endogenous metabolism. Several spatialized metabolic engineering strategies including metabolon construction (protein level), sub-organelle engineering (subcellular level), and co-culture engineering (cell level) have been developed to address these problems.

Construction of metabolon is beneficial for substrate channeling by preventing unstable intermediates or relieving toxicity of some intermediates ([@bib2]). There are two ways to construct a metabolon: protein fusion ([Figure 5](#fig5){ref-type="fig"}C) and protein scaffold ([Figure 5](#fig5){ref-type="fig"}D). Protein fusion is the most convenient strategy for enhancing substrate channeling ([@bib222]), which, however, may destroy the enzyme structure and is always limited to two enzymes ([Figure 5](#fig5){ref-type="fig"}C). Protein scaffold can gather several enzymes into proximity by affinity binding, which has been successfully applied in *S*. *cerevisiae* for improving resveratrol production ([@bib195]) and also xylose utilization with diminished the accumulation of by-product xylitol by co-localizing corresponding enzymes ([@bib181]).

Sub-organelle compartmentalization can provide suitable physicochemical environments and enough precursors/enzymes for complicated biosynthetic pathways ([Figure 5](#fig5){ref-type="fig"}E). The benefits of targeting biosynthetic pathways to subcellular compartments were reviewed previously, including mitochondria, peroxisomes, ER, Golgi, vacuoles, and cell wall, in different yeast species ([@bib2], [@bib64]). The first example showed that mitochondrial compartmentalization of the tailoring P450 enzyme improved hydrocortisone production, because mitochondria are more suitable for maintaining P450 activity ([@bib176]). Recently, mitochondrial compartmentalization was showed to be helpful for production of isoprenoids ([@bib53], [@bib209], [@bib211]), short-chain alcohols ([@bib6]), and chemicals (acetoin and fumarate) ([@bib26], [@bib94]), because of sufficient supply of acetyl-CoA and tricarboxylic acid cycle intermediates. However, it may bring stresses when overexpressing enzymes in mitochondria that are crowded with respiration components. Some other sub-organelles, such as peroxisomes, lipid bodies, and vacuoles, are relatively orthogonal to the native essential process, making them ideal workhorses for metabolic compartmentalization. Furthermore, it has been showed that peroxisome compartmentalization of CoA-tailoring steps was required for efficient biosynthesis of penicillin ([@bib125]) and mycophenolic acid ([@bib215]) in fungi, indicating that peroxisomes are ideal catalyzing houses for natural product biosynthesis. Peroxisomal targeting improved the production of fatty acid-derived molecules by up to 700% with relieved side pathway competition ([@bib224], [@bib228]). Recently, peroxisome compartmentalization enabled high-level production of the triterpene squalene in *S*. *cerevisiae*, which suggested that peroxisomes were promising subcellular factories for terpene biosynthesis ([@bib112]). Peroxisome compartmentalization of prodeoxyviolacein (PDV) biosynthetic pathway reduced the accumulation of by-product chromopyrrolic acid, although without improving PDV production ([@bib41]), which indicated that the precursor might be insufficient. It is much more challenging to provide high flux of precursor for biosynthesis of heterologous natural products other than fatty acid or acetyl-CoA derivatives in peroxisome, which are the main organelles for fatty acid degradation in yeast. Similarly, compartmentalization of associated pathways in lipid droplet and other lipid-relevant organelles resulted in a 10 times higher production of fatty acid methyl esters when compared with the cytosolic pathway in *Y*. *lipolytica* ([@bib206]). Recently, a synthetic non-endogenous nanoscale compartment was constructed in yeast by expressing prokaryotic encapsulins ([@bib90]), which represented a strictly orthogonal compartment. Engineering organelle size and biogenesis can provide more space for enzyme encapsulation and product storage. Enlarging lipid droplets increased lycopene production by 25%, which might improve the storage of hydrophilic lycopene ([@bib118]). Similarly, expanding ER resulted in an 8-fold higher production of protopanaxadiol ([@bib82]) and a 7.1-fold increase of protein secretion ([@bib10]), which demonstrated that ER space expansion increased the capacity of ER protein synthesis and folding and thus relieved metabolic constraints imposed by limited enzyme abundance.

### Co-culture and Stepwise Culture Engineering {#sec1.4.4}

Non-linear biosynthetic pathways, such as diverging and converging pathways, are particularly challenging in pathway optimization in mono-culture system, because they require a delicate balancing between all interconnected pathway modules ([@bib212]). Furthermore, functional expression of multiple genes from various species may require different cellular environments, which is difficult in a single organism. The emergence of modular co-culture engineering offers a feasible approach for modularizing and balancing complicated biosynthetic pathways ([Figure 5](#fig5){ref-type="fig"}F), whose application in production of natural products has just been comprehensively reviewed ([@bib194]). The optimized multiple-strain culture of same species such as *E*. *coli* showed 38-fold higher production of rosmarinic acid over the mono-culture system ([@bib99]). Construction of chimeric *S*. *cerevisiae*-*E*.*coli* co-cultures enabled high-level production of oxygenated terpenoids, by taking advantage of the high-efficiency terpene biosynthesis in *E*. *coli* and suitable environment of *S*. *cerevisiae* for P450 expression ([@bib223]). Engineering co-culture methylotrophic yeasts *K*. *phaffii* (two strains) enabled 50% to 70% higher production of polyketide drug monacolin J and lovastatin than that from mono-culture by relieving metabolic stress ([@bib106]). Stepwise fermentation is consequently culturing multiple strains that harbor divided modules of complicated biosynthetic pathways. The opiate biosynthetic pathway was divided into four modules and distributed into four *E*. *coli* strains ([@bib131]), and stepwise culture of four engineered strains produced 2.1 mg/L thebaine from glycerol, corresponding to a 300-fold increase from yeast system ([@bib173]). This stepwise culture system can avoid tetrahydropapaveroline (THP) degradation by *o*-diphenolase activity of tyrosinase ([@bib133]).

Although modular co-culture has some unique advantages over monoculture, there are still some major obstacles to overcome for large-scale industrial applications. The biggest obstacle is coordinating multiple microbial groups into stable synthetic consortia. The strategies of commensalism-based or mutualistic synthetic consortia might be a way out ([@bib167], [@bib223]). However, little is known about the specific principles of cooperation and competition in these mutualistic models. When these interactions scale to higher dimensions, the behaviors of complex ecosystems are even more elusive ([@bib124]). In addition, achieving a balance of metabolic ratios among different modules and efficient delivery of intermediates may also be obstacles for the application of co-culture strategy.

The Global Regulation {#sec1.5}
---------------------

In addition to the pathway engineering and flux rewiring, enhancing the robustness of microbial cell factories is essential for industrial application with improved resistance to harsh industrial conditions and toxicity of natural products ([@bib59]). Engineering cellular tolerance against harsh conditions has been discussed in detail in previous reviews by us and others ([@bib59], [@bib226]). Here we emphasize the global regulation of cellular performance for natural biosynthesis by directed evolution and population quality control.

### Directed Evolution at the Level of the Whole Organism {#sec1.5.1}

Directed evolution at the cellular level emphasizes "collaboration" between scientists and microorganisms to achieve design goals, harnessing the initiative of the yeast rather than relying entirely on biologists\' deliberate choices ([@bib177]). This global-directed evolution strategy often requires yeast to adapt to challenging environments by genomic flexibility and DNA recombination that are very difficult to realize through rational engineering. Similar to protein-directed evolution, cellular-directed evolution requires efficient mutagenesis and high-throughput screening. Adaptive laboratory evolution of *S*. *cerevisiae* toward enhanced resistance of periodic hydrogen peroxide shocking improved carotenoid production by exploiting the antioxidant properties of carotenoids ([@bib152]). Similarly, this "hydrogen peroxide-shocking" strategy also improved the production of antioxidant 3′-hydroxygenistein in recombinant *K*. *phaffii* ([@bib190]). Incorporating the synthetic chromosome rearrangement and modification by *loxP*-mediated evolution into designed yeast cells with *loxP* sites enabled generation of genotype diversity for improved production of carotenoids, violacein, and penicillin in yeast ([@bib14], [@bib75], [@bib104]). Further high-throughput sequencing can map genotype-phenotype relationships, which is helpful for the construction of robust cell factories by reverse engineering ([@bib210]). Together with random mutations, directed evolution can be combined with rational designs to form a loop, which in turn provides the targets for future rational design and regulation.

### Population Quality Control {#sec1.5.2}

Nongenetic variation is naturally inherent and will lead to suboptimal performance at the ensemble level due to the subpopulations of low-performance variants consuming nutrients without efficiently synthesizing products. It was found that a minority (15%) of the total cell population produced more than half of the total free fatty acid in an engineered *E*. *coli*, which indicated that most cells performed very weakly ([@bib202]). To our knowledge, there is no report on engineering population quality control in yeast for production of natural products, which might be attributed to the challenge in coupling the cellular fitness with natural product biosynthesis, although genetic circuits such as dual feedback loops have been shown to suppress cellular heterogeneity in yeast ([@bib151]).

Perspective {#sec1.6}
-----------

Non-conventional yeast refers to more than 2,000 identified yeast species except for two model yeasts, *S*. *cerevisiae* and *Schizosaccharomyces pombe* ([@bib150]). Several non-conventional yeasts have attracted more interest in metabolic engineering applications because of their unique advantages and characteristics ([@bib186]). In contrast to the Crabtree yeast *S*. *cerevisiae*, many con-conventional yeasts are Crabtree negative, have much higher biosynthetic capacity, and use low-cost or market-surplus carbon sources, such as methanol or glycerol ([@bib36], [@bib121], [@bib200]). *K*. *phaffii* has been known as a powerful protein expression system because of its capacity to perform complex post-translational modifications ([@bib207]). *Ogataea polymorpha* and *Ogataea thermomethanolica* are thermo-tolerant yeast and have high potential for industrial application along with saving cooling cost ([@bib158]). These characteristics and advantages of non-conventional yeasts make them more suitable as hosts than *S*. *cerevisiae* for specific production ([@bib45]). It should be emphasized that fungi such as *Aspergillus* are much more suitable as cell factories for heterologous production of complicated antibiotics that are derived from fungi ([@bib169]). However, lack of genetic tools and inefficient homologous recombination (HR) make it challenging in engineering these microbes ([@bib18]).

Engineering natural product production always involves construction of complex and long pathways with multiple genes ([@bib97], [@bib111]), which requires efficient gene editing platform for high-fidelity assembly of long DNA fragments. With the rapid development of DNA chemical synthesis services, a series of long DNA fragment assembly techniques have been introduced, including polymerase cycling assembly (PCA) ([@bib170]), emulsion PCA ([@bib146]), ligase cycling assembly ([@bib39]), Gibson assembly ([@bib58]), and golden gate assembly ([@bib51]). However, sequence mismatch or errors always happen at special DNA assembly, such as long repeat sequence and hairpin loop structure, which hinder the precise construction of biosynthetic pathways. Therefore, bioinformatics and sequence optimization might be promising solutions.

Recently, the CRISPR-Cas9 system has emerged as a powerful gene editing tool for metabolic engineering and synthetic biology, which has worked well in organisms including model microorganism *S*. *cerevisiae* and *E*. *coli*. A vast number of Cas9-mediated genetic tools enabled efficient and rapid genetic editing in *S*. *cerevisiae* ([@bib101]). Furthermore, numerous genetic manipulation toolboxes were developed for the construction of heterologous pathways, including promoters ([@bib175]), terminators ([@bib35], [@bib203]), and neutral sites ([@bib127]). These genetic toolboxes make *S*. *cerevisiae* the most attractive cell factory for the production of natural products. As mentioned above, most of non-conventional yeasts display a stronger preference for non-homologous end joining (NHEJ) when exogenous DNA is introduced, which hampers the precise genetic editing in metabolic engineering ([@bib185]). Although this problem has been alleviated to some extent through the regulation of the HR- or NHEJ-related proteins such as Rad52p ([@bib168]), Ku70p ([@bib109]), and Ku80p ([@bib165]), the HR efficiency is still far less for precise genetic engineering, in particular multiple DNA fragment assembly. Besides efficient genetic editing, non-conventional yeast systems require an expanded synthetic biology toolbox (such as highly controllable promoters and enough terminators without homologous sequences) for pathway construction.

Current cell factory construction mainly focuses on enhancing precursor supply, enzyme engineering, and flux balancing. However, the cofactors that are essential for enzyme activity have always been ignored. In particular, many catalytic enzymes of natural product biosynthesis require the specific cofactors, but heterologous hosts such yeasts have insufficient cofactor supply. Although some strategies have been developed for cofactor engineering, we still know very little about the regulation mechanism of cellular cofactor equilibrium. On the other hand, the variation of cofactor biosynthesis and regulation among different organisms poses a huge challenge for the cofactor engineering in cell factories. Thus, it is essential to illuminate the cellular cofactor biosynthesis, distribution and transportation in yeast for cofactor regulation. Artificial intelligence (AI) provides an opportunity for speeding up DBTL cycles by computer automatic design and optimization. The computer-aided design (CAD) systems have greatly improved the design quality and documentation communications, and created shareable databases for manufacturing. Recently, deep neural networks were trained from published reactions in organic chemistry, which enabled the discovery of retrosynthetic routes and resulted in faster and more selective synthesis than traditional methods ([@bib166]). Some attempts have also been made in synthetic biology. An automated DBTL pipeline succeeded in improving the production of flavonoid (2S)-pinocembrin in *E*. *coli* ([@bib20]). Another computational platform ClusterCAD formalized a paradigm for the design of PKS (type I modular polyketide synthase) chimeras and streamlined the process of designing experiments to test strategies for engineering PKS variants ([@bib50]). However, the complexity and nonlinearity of biological systems makes it challenging in precise modeling and operation and thus needs novel and robust computational tools. The current protein design platforms rely on the homology of existing proteins at different resolutions and accurately predicting the structure of a novel protein is still challenging so far ([@bib4], [@bib38]), not to mention the design of complex biological systems. Building an interoperable and reliable standard database is a prerequisite in biological engineering, which will be beneficial for rapid integration of data, continuous self-renewing of biological DBTL cycles, and automated design of metabolic pathways and molecules.

In summary, the yeast cells are ideal workhorses for overproduction of natural products, and advanced synthetic biology and systems biology can accelerate the rising of yeast cell factory for industrial application.
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